10x Genomics' Xenium Platform To Be Deployed By Fudan University Shanghai Cancer Center, Shanghai Precision Diagnostics In 24-Month Trial

10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today announced that Fudan University Shanghai Cancer Center (FUSCC) and Shanghai Precision Diagnostics Co. Ltd (SPDx), will deploy its Xenium platform in a 24-month study. The project seeks to identify biomarkers that may predict how patients with breast cancer respond to neoadjuvant therapy, or treatment administered before surgery to shrink tumors. FUSCC and SPDx intend to use the findings from the study to inform their development of potential future diagnostic approaches.